Fundraising Rounds off a Successful Year for Interrad

LGB - February 2023

LGB & Co. Limited has acted as placing agent for the issuance of two and three year notes that have enabled Interrad Medical Inc. to raise $5.6 million. The company is well positioned to make subcutaneous securement of catheters the global standard of care in 2023.

Interrad has developed the SecurAcath Subcutaneous Catheter Securement System (www.securacath.com). This simple, yet revolutionary device, makes it possible to hold virtually any catheter securely in place without sutures or adhesives. The device improves patient outcomes and healthcare costs by reducing incidents of dislodgement and infection. Although based in Minneapolis, the company first achieved commercial success with NICE Guidance and the adoption of SecurAcath by NHS England in 2016. 

The fundraising followed steady business progress during 2022. In particular, Interrad entered into a US distribution partnership with Eloquest Healthcare and signed a contract with Vizient, which provides central procurement services to more than 50% of US hospitals. SecurAcath is now being marketed alongside Eloquest’s complementary products by its sales team of 25. Previously, Interrad had a team of only three people working with hospitals in the US. In addition to marketing, Eloquest is handling the organisation of evaluations and adoptions, which are resource-intensive. Interrad has responsibility for fulfilment and invoicing, thus retaining its relationships with hospitals. In addition, a number of new distribution agreements have been signed outside the US. SecurAcath will shortly be offered in Brazil, which is a market of great potential.


The company’s proposition to healthcare providers and patients is underpinned by more than 25 third-party clinical studies. In October 2022 the Journal of the Association for Vascular Access published a paper by Bell, et al. called a Systematic Review of the Safety and Efficacy of Central Venous Access Device (CVAD) Securement. Researchers reviewed reviewed more than 8,000 published studies to examine safety and efficacy outcomes related to CVAD securement. In the studies with good comparative data on rates of catheter migration and dislodgement, researchers found clear benefits for the SecurAcath. The median incidence of migration and dislodgement of SecurAcath was just 1.76%, compared to 6.77% for suture-based systems, and 9.69% for adhesive securement devices.

In addition, a presentation was made at the World Congress on Vascular Access (WoCoVA) in Athens also in October. The presentation was entitled: A Decade of Security by McCormick, et al. from the Clatterbridge Cancer Centre, NHS Trust in Liverpool. Data on patients with SecurAcath and an adhesive device and removal data were collected from 2009 to 2020. The research covered 9,257 patients and a total of 1,251,613 catheter days. The probability of reaching the end of need for one peripherally inserted catheter for patients with an adhesive securement device was only 68% at two years compared to over 95% for patients with SecurAcath. Moreover, migration and dislodgement causing premature removal of the catheter occurred at a rate of 12% for catheters secured with an adhesive device compared with 0.4% for those with SecurAcath.

 

The company is engaging with strategic counterparties in the vascular access sector with a view to achieving a liquidity event for current investors and making subcutaneous securement available to healthcare providers worldwide. Interrad’s patent portfolio provides exclusive rights to the subcutaneous securement of a catheter or tube in a medical setting and so a strategic partner could extend the concept well beyond the current SecurAcath product range.